If you use the generic name, you will probably get lots of hits: one for when the molecule was first being introduced to the market plus hits for subsequent generic versions. The FDA does its review for efficacy and safety when the molecule is first introduced to the market. Years later, when the patent expires, generic equivalents get approved, but what the FDA cares about at this stage is bioequivalence (in terms of blood levels) to the original brand name version. Thus generics do not have to demonstrate efficacy and safety all over again, which is why these approval packages generally contain little or no such data.
